<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03809000</url>
  </required_header>
  <id_info>
    <org_study_id>RTOG 3506</org_study_id>
    <secondary_id>STEEL</secondary_id>
    <nct_id>NCT03809000</nct_id>
  </id_info>
  <brief_title>A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery</brief_title>
  <acronym>STEEL</acronym>
  <official_title>STEEL: A Randomized Phase II Trial of Salvage Radiotherapy With Standard vs Enhanced Androgen Deprivation Therapy (With Enzalutamide) in Patients With Post-Prostatectomy PSA Recurrences With Aggressive Disease Features</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RTOG Foundation, Inc.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>RTOG Foundation, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with post-prostatectomy PSA (Prostate Specific Antigen) recurrences with aggressive
      disease features will receive salvage radiation therapy and standard androgen deprivation
      therapy (ADT) or enhanced ADT to determine if there is any improvement in progression-free
      survival when enhanced ADT is used compared to standard ADT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:

      To determine whether, in men with post-prostatectomy PSA (prostate specific antigen)
      recurrences with aggressive disease features, salvage radiotherapy (SRT) with enhanced
      androgen deprivation therapy (ADT), consisting of enzalutamide (MDV3100) and a GnRH analog,
      will improve progression-free survival compared to SRT with standard GnRH analog -based ADT.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 15, 2019</start_date>
  <completion_date type="Anticipated">September 15, 2029</completion_date>
  <primary_completion_date type="Anticipated">September 15, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>From the date of randomization to the date of progression, death from any cause or last known follow-up date, assessed up to 5 years.</time_frame>
    <description>The time from the date of randomization to the date of progression, death from any cause or last known follow-up date.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">242</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Salvage Radiation Therapy + Standard ADT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Salvage RT will be given up to 66.60 Gy along with 24 months of a GnRH analog with or without 1-4 months of bicalutamide.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salvage Radiation Therapy + Enhanced ADT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Salvage RT will be given up to 66.60 Gy along with 24 months of a GnRH analog + 24 months of enzalutamide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Radiation Therapy</description>
    <arm_group_label>Salvage Radiation Therapy + Enhanced ADT</arm_group_label>
    <arm_group_label>Salvage Radiation Therapy + Standard ADT</arm_group_label>
    <other_name>RT</other_name>
    <other_name>Three-Dimensional Conformal Radiation Therapy (3D-CRT)</other_name>
    <other_name>Intensity-Modulated Radiation Therapy (IMRT)</other_name>
    <other_name>Image-Guided Radiation Therapy (IGRT)</other_name>
    <other_name>Radiotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>Anti-androgen</description>
    <arm_group_label>Salvage Radiation Therapy + Enhanced ADT</arm_group_label>
    <other_name>Xtandi®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bicalutamide</intervention_name>
    <description>Anti-androgen</description>
    <arm_group_label>Salvage Radiation Therapy + Standard ADT</arm_group_label>
    <other_name>Casodex®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH analog</intervention_name>
    <description>Anti-androgen</description>
    <arm_group_label>Salvage Radiation Therapy + Enhanced ADT</arm_group_label>
    <arm_group_label>Salvage Radiation Therapy + Standard ADT</arm_group_label>
    <other_name>Gonadotropin-releasing hormone analog</other_name>
    <other_name>Lupron®</other_name>
    <other_name>leuprolide acetate</other_name>
    <other_name>goserelin acetate</other_name>
    <other_name>Eligard™</other_name>
    <other_name>Viadur™</other_name>
    <other_name>Zoldaex®</other_name>
    <other_name>Trelstar®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pathologically (histologically) proven adenocarcinoma confirmed by prostatectomy
             performed within 10 years prior to registration and any type of radical prostatectomy
             is permitted, including retropubic, perineal, laparoscopic or robotically assisted.

          -  PSA level (≥ 0.7 ng/mL) within 90 days prior to registration. GnRH analog may be
             started no more than 42 days prior study entry, but patients must have a PSA ≥ 0.7
             ng/mL prior to starting ADT.

          -  Hemoglobin ≥ 9.0 g/dL, independent of transfusion and/or growth factors within 90 days
             prior to registration.

          -  Platelet count ≥ 75,000 x 109/µL independent of transfusion and/or growth factors
             within 90 days prior to registration.

          -  At least 1 of the following aggressive features:

               -  Gleason score of 8-10 (note any Gleason score is eligible)

               -  Seminal vesicle invasion (SVI) (note any pT stage [AJCC v8.0] is eligible but a
                  pT stage

                  ≥ pT3b is considered aggressive)

               -  Locoregional node involvement at radical prostatectomy (pN1)

               -  Persistently elevated PSA post-RP nadir (PEPP) defined as PSA &gt; 0.1 ng/mL after
                  radical prostatectomy

          -  Serum albumin ≥ 3.0 g/dL within 90 days prior to registration

          -  GFR &gt;35 mL/min estimated by Cockcroft-Gault or measured directly by 24 hour urine
             creatinine within 90 days prior to registration.

          -  Serum total bilirubin ≤1.5 × ULN (Note: In subjects with Gilbert's syndrome, if total
             bilirubin is &gt;1.5 × ULN, measure direct and indirect bilirubin and if direct bilirubin
             is ≤1.5 × ULN, subject is eligible) within 90 days prior to registration.

          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &lt;2.5 × ULN within
             90 days prior to registration.

          -  Testosterone &gt;50 ng/dL within 90 days prior to registration. Prior androgen
             deprivation (GnRH analog and/or non-steroidal antiandrogen) therapy is allowed
             provided that serum testosterone concentration must be ≥ 50 ng/dL prior to
             registration or starting ADT, whichever occurs first; 5-alpha reductase inhibitors
             will not impact eligibility, but must be discontinued prior to starting protocol
             treatment.

          -  History and physical with ECOG Performance Status 0-1 or within 90 days prior to
             registration.

        Exclusion Criteria:

          -  Definitive clinical or radiologic evidence of metastatic disease with the exception of
             locoregional lymph nodes.

          -  Prior invasive malignancy (except non-melanomatous skin cancer carcinoma in situ of
             the male breast, penis, oral cavity, or stage Ta of the bladder, or stage I completely
             resected melanoma) unless disease free for a minimum of 2 years).

          -  Prior systemic chemotherapy for the study cancer. Note: prior chemotherapy for a
             different cancer is allowable.

          -  Prior radiotherapy to the region of the study cancer that would result in overlap of
             radiation therapy fields.

          -  History of any of the following:

               -  Documented inflammatory bowel disease

               -  Transmural myocardial infarction within the last 4 months prior to registration.

               -  Unstable angina and/or congestive heart failure requiring hospitalization within
                  the last 4 months prior to registration

               -  Seizure disorder or condition that may predispose to seizure (e.g. prior cortical
                  stroke or significant brain trauma)

               -  Uncontrolled hypertension defined as a sustained systolic blood pressure in
                  excess of 150 mmHg or a sustained diastolic blood pressure in excess of 90 mmHg
                  despite optimized antihypertensive therapy.

          -  Known gastrointestinal disorder affecting absorption of oral medications.

          -  Active uncontrolled infection defined as an identified infectious condition that
             requires active therapy that has not yet been completed.

          -  HIV positive patients with CD4 count &lt; 200 cells/microliter within 30 days prior to
             registration OR HIV patients under treatment with highly active antiretroviral therapy
             (HAART) within 30 days prior to registration regardless of CD4 count. Note: HIV
             testing is not required for eligibility for this protocol as it is self-reported. This
             exclusion criterion is necessary because the treatments involved in this protocol may
             be immunosuppressive and/or interact with HAART.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edwin Posadas, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RTOG Foundation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Felix Feng, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RTOG Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Edwin Posadas, MD</last_name>
    <phone>310-423-7600</phone>
    <email>edwin.posadas@csmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Arizona Center for Cancer Care - Gilbert</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85297</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Bush</last_name>
      <phone>623-414-4921</phone>
      <email>tbush@arizonaccc.com</email>
    </contact>
    <investigator>
      <last_name>Terry Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Center for Cancer Care - Peoria</name>
      <address>
        <city>Peoria</city>
        <state>Arizona</state>
        <zip>85381</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Bush</last_name>
      <phone>623-414-4921</phone>
      <email>tbush@arizonaccc.com</email>
    </contact>
    <investigator>
      <last_name>Terry Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Center for Cancer Care - Phoenix</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85027</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Bush</last_name>
      <phone>623-414-4921</phone>
      <email>tbush@arizonaccc.com</email>
    </contact>
    <investigator>
      <last_name>Terry Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Center for Cancer Care - Scottsdale East</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Bush</last_name>
      <phone>623-414-4921</phone>
      <email>tbush@arizonaccc.com</email>
    </contact>
    <investigator>
      <last_name>Terry Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Center for Cancer Care - Scottsdale North</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Bush</last_name>
      <phone>623-414-4921</phone>
      <email>tbush@arizonaccc.com</email>
    </contact>
    <investigator>
      <last_name>Terry Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Center for Cancer Care - Surprise</name>
      <address>
        <city>Surprise</city>
        <state>Arizona</state>
        <zip>85374</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tina Bush</last_name>
      <phone>623-414-4921</phone>
      <email>tbush@arizonaccc.com</email>
    </contact>
    <investigator>
      <last_name>Terry Lee, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marin Cancer Care, Inc.</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Chang</last_name>
      <phone>415-925-5040</phone>
      <email>jchang@marincancercare.com</email>
    </contact>
    <investigator>
      <last_name>Llyod Miyawaki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Marin Health Medical Center</name>
      <address>
        <city>Greenbrae</city>
        <state>California</state>
        <zip>94904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Chang</last_name>
      <phone>415-925-5040</phone>
      <email>jchang@marincancercare.com</email>
    </contact>
    <investigator>
      <last_name>Lloyd Miyawaki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roseville Radiation Oncology Center</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Pierini</last_name>
      <phone>916-454-6994</phone>
      <email>pierinmm@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Roseville Medical Center</name>
      <address>
        <city>Roseville</city>
        <state>California</state>
        <zip>95661</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Pierini</last_name>
      <phone>916-454-6994</phone>
      <email>pierinimm@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sutter Medical Center Sacramento</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95816</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Pierini</last_name>
      <phone>916-454-6994</phone>
      <email>Pierinimm@sutterhealth.org</email>
    </contact>
    <investigator>
      <last_name>Christopher Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Valley View Hospital Cancer Center</name>
      <address>
        <city>Glenwood Springs</city>
        <state>Colorado</state>
        <zip>81601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Page</last_name>
      <phone>970-384-7574</phone>
      <email>cheryl.page@vvh.org</email>
    </contact>
    <investigator>
      <last_name>Peter Rossi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nancy N. &amp; J.C. Lewis Cancer &amp; Research Pavilion</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31405</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Meyers</last_name>
      <phone>912-819-8236</phone>
      <email>meyersc@sjchs.org</email>
    </contact>
    <investigator>
      <last_name>John Pablo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Decatur Memorial Hospital</name>
      <address>
        <city>Decatur</city>
        <state>Illinois</state>
        <zip>62526</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dianna Richardson</last_name>
      <phone>217-876-4760</phone>
      <email>drichardson@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>Harold Yoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Crossroads Cancer Center</name>
      <address>
        <city>Effingham</city>
        <state>Illinois</state>
        <zip>62401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dianna Richardson</last_name>
      <phone>217-876-4760</phone>
      <email>drichardson@dmhhs.org</email>
    </contact>
    <investigator>
      <last_name>Harold Yoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Coastal Cancer Treatment Center - Bath</name>
      <address>
        <city>Bath</city>
        <state>Maine</state>
        <zip>04530</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Dalton, RN</last_name>
      <phone>207-294-8291</phone>
      <email>jdalton@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Matthew Chaney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Waldo Count General Hospital - Belfast</name>
      <address>
        <city>Belfast</city>
        <state>Maine</state>
        <zip>04915</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Dalton, RN</last_name>
      <phone>207-294-8291</phone>
      <email>jdalton@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Matthew Chaney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Health/SMHC Cancer Care and Blood Disorders-Biddeford</name>
      <address>
        <city>Biddeford</city>
        <state>Maine</state>
        <zip>04005</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Dalton, RN</last_name>
      <phone>207-294-8291</phone>
      <email>jdalton@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Matthew Chaney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Health/Stephens Memorial - Norway</name>
      <address>
        <city>Norway</city>
        <state>Maine</state>
        <zip>04268</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Dalton, RN</last_name>
      <phone>207-294-8291</phone>
    </contact>
    <investigator>
      <last_name>Matthew Chaney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Medical Center - Bramhall S Portland</name>
      <address>
        <city>Portland</city>
        <state>Maine</state>
        <zip>04102</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Dalton, RN</last_name>
      <phone>207-294-8291</phone>
      <email>jdalton@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Matthew Chaney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Penobscot Bay Medical Center - Rockport</name>
      <address>
        <city>Rockport</city>
        <state>Maine</state>
        <zip>04856</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Dalton, RN</last_name>
      <phone>207-294-8291</phone>
      <email>jdalton@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Matthew Dalton, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Health CC of York County - Sanford</name>
      <address>
        <city>Sanford</city>
        <state>Maine</state>
        <zip>04073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Dalton, RN</last_name>
      <phone>207-294-8291</phone>
      <email>jdalton@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Matthew Chaney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Health/SMHCancer Care and Blood Disorders - Sanford</name>
      <address>
        <city>Sanford</city>
        <state>Maine</state>
        <zip>04073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Dalton, RN</last_name>
      <phone>207-294-8291</phone>
      <email>jdalton@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Matthew Chaney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Medical Cancer Center - Scarborough Campus</name>
      <address>
        <city>Scarborough</city>
        <state>Maine</state>
        <zip>04074</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Dalton, RN</last_name>
      <phone>207-294-8291</phone>
      <email>jdalton@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Matthew Chaney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maine Medical Partners - South Portland</name>
      <address>
        <city>South Portland</city>
        <state>Maine</state>
        <zip>04106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Dalton, RN</last_name>
      <phone>207-294-8291</phone>
      <email>jdalton@mmc.org</email>
    </contact>
    <investigator>
      <last_name>Matthew Chaney, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McLaren Cancer Institute - Bloomfield</name>
      <address>
        <city>Bloomfield</city>
        <state>Michigan</state>
        <zip>48302</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delaney Erickson</last_name>
      <phone>313-576-8029</phone>
      <email>ericksod@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Kiran Devisetty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>21st Century Oncology MHP - Clarkston</name>
      <address>
        <city>Clarkston</city>
        <state>Michigan</state>
        <zip>48346</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolf Ross</last_name>
      <phone>941-833-5700</phone>
      <email>rudi.ross@21co.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Boike, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McLaren Cancer Institute - Clarkston</name>
      <address>
        <city>Clarkston</city>
        <state>Michigan</state>
        <zip>48346</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delaney Erickson</last_name>
      <phone>313-576-8029</phone>
      <email>ericksod@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Kiran Devisetty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital - Dearborn</name>
      <address>
        <city>Dearborn</city>
        <state>Michigan</state>
        <zip>48124</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Lurie</last_name>
      <phone>248-551-0735</phone>
      <email>melissa.lurie@beaumont.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Krauss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wayne State/Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delaney Erickson</last_name>
      <phone>313-576-8029</phone>
      <email>ericksod@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Kiran Devisetty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>21st Century Oncology MHP - Farmington</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48334</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolf Ross</last_name>
      <phone>941-833-5700</phone>
      <email>rudi.ross@21co.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Boike, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McLaren Cancer Institute - Flint</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48532</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delaney Erickson</last_name>
      <phone>313-576-8029</phone>
      <email>ericksod@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Kiran Devisetty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Singh and Arora Hematology Oncology PC</name>
      <address>
        <city>Flint</city>
        <state>Michigan</state>
        <zip>48532</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delaney Erickson</last_name>
      <phone>313-576-8029</phone>
      <email>ericksod@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Kiran Devisetty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McLaren Cancer Institute - Greater Lansing</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48910</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delaney Erickson</last_name>
      <phone>313-576-8029</phone>
      <email>ericksod@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Kiran Devisetty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid-Michigan Physicians - Lansing</name>
      <address>
        <city>Lansing</city>
        <state>Michigan</state>
        <zip>48912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delaney Erickson</last_name>
      <phone>313-576-8029</phone>
      <email>ericksod@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Kiran Devisetty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McLaren Cancer Institute - Lapeer Region</name>
      <address>
        <city>Lapeer</city>
        <state>Michigan</state>
        <zip>48446</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delaney Erickson</last_name>
      <phone>313-576-8029</phone>
      <email>ericksod@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Kiran Devisetty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>21st Century Oncology MHP - Macomb</name>
      <address>
        <city>Macomb</city>
        <state>Michigan</state>
        <zip>48044</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolf Ross</last_name>
      <phone>941-833-5700</phone>
      <email>rudi.ross@21co.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Boike, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>21st Century Oncology MHP - Madison Heights</name>
      <address>
        <city>Madison Heights</city>
        <state>Michigan</state>
        <zip>48071</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolf Ross</last_name>
      <phone>941-833-5700</phone>
      <email>rudi.ross@21co.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Boike, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McLaren Cancer Institute - Macomb</name>
      <address>
        <city>Mount Clemens</city>
        <state>Michigan</state>
        <zip>48043</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delaney Erickson</last_name>
      <phone>313-576-8029</phone>
      <email>ericksod@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Kiran Devisetty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McLaren Cancer Institute - Central Michigan</name>
      <address>
        <city>Mount Pleasant</city>
        <state>Michigan</state>
        <zip>48858</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delaney Erickson</last_name>
      <phone>313-576-8029</phone>
      <email>ericksod@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Kiran Devisetty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McLaren Cancer Institute - Owosso</name>
      <address>
        <city>Owosso</city>
        <state>Michigan</state>
        <zip>48867</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delaney Erickson</last_name>
      <phone>313-576-8029</phone>
      <email>ericksod@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Kiran Devisetty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McLaren Cancer Institute - Northern Michigan</name>
      <address>
        <city>Petoskey</city>
        <state>Michigan</state>
        <zip>49770</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delaney Erickson</last_name>
      <phone>313-576-8029</phone>
      <email>ericksod@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Kiran Devisetty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>McLaren Cancer Institute - Port Huron</name>
      <address>
        <city>Port Huron</city>
        <state>Michigan</state>
        <zip>48060</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Delaney Erickson</last_name>
      <phone>313-576-8029</phone>
      <email>ericksod@karmanos.org</email>
    </contact>
    <investigator>
      <last_name>Kiran Devisetty, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital - Royal Oak</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Lurie</last_name>
      <phone>248-551-0735</phone>
      <email>melissa.lurie@beaumont.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Krauss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William Beaumont Hospital - Troy</name>
      <address>
        <city>Sterling Heights</city>
        <state>Michigan</state>
        <zip>48314</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Lurie</last_name>
      <phone>248-551-0735</phone>
      <email>melissa.lurie@beaumont.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Krauss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>21st Century Oncology MHP - Troy</name>
      <address>
        <city>Troy</city>
        <state>Michigan</state>
        <zip>48098</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rudolf Ross</last_name>
      <phone>941-833-5700</phone>
      <email>rudi.ross@21co.com</email>
    </contact>
    <investigator>
      <last_name>Thomas Boike, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paige Lampe</last_name>
      <phone>314-273-3925</phone>
      <email>lampepe@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Hiram Gay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Schoville</last_name>
      <phone>603-650-6056</phone>
      <email>sharon.r.schoville@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Alan Hartford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Physicians at Oneida</name>
      <address>
        <city>Oneida</city>
        <state>New York</state>
        <zip>13421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Bingham</last_name>
      <phone>315-464-3603</phone>
      <email>binghame@upstate.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Bogart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Upstate Cancer Center Radiation Oncology at Oneida</name>
      <address>
        <city>Oneida</city>
        <state>New York</state>
        <zip>13421</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Bingham</last_name>
      <phone>315-464-3603</phone>
      <email>binghame@upstate.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Bogart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Physicians at Oswego</name>
      <address>
        <city>Oswego</city>
        <state>New York</state>
        <zip>13126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Bingham</last_name>
      <phone>315-464-3603</phone>
      <email>binghame@upstate.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffery Bogart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Upstate Cancer Radiation Oncology at Oswego</name>
      <address>
        <city>Oswego</city>
        <state>New York</state>
        <zip>13126</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Bingham</last_name>
      <phone>315-464-3603</phone>
      <email>binghame@upstate.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Bogart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SUNY Upstate Medical University</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Bingham</last_name>
      <phone>315-464-3603</phone>
      <email>binghame@upstate.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Bogart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Upstate Cancer Center at Hill Radiation Oncology</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erin Bingham</last_name>
      <phone>315-464-3603</phone>
      <email>binghame@upstate.edu</email>
    </contact>
    <investigator>
      <last_name>Jeffrey Bogart, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WellSpan Health - Ephrata Cancer Center</name>
      <address>
        <city>Ephrata</city>
        <state>Pennsylvania</state>
        <zip>17522</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debi Oxenberg</last_name>
      <phone>717-741-8124</phone>
      <email>doxenberg@wellspan.org</email>
    </contact>
    <investigator>
      <last_name>Amit Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WellSpan Health - Adams Cancer Center</name>
      <address>
        <city>Gettysburg</city>
        <state>Pennsylvania</state>
        <zip>17325</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debi Oxenberg</last_name>
      <phone>717-741-8124</phone>
      <email>doxenbery@wellspan.org</email>
    </contact>
    <investigator>
      <last_name>Amit Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WellSpan Health - Sechler Family Cancer Center</name>
      <address>
        <city>Lebanon</city>
        <state>Pennsylvania</state>
        <zip>17402</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debi Oxenberg</last_name>
      <phone>717-741-8124</phone>
      <email>doxenberg@wellspan.org</email>
    </contact>
    <investigator>
      <last_name>Amit Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>WellSpan Health - York Hospital</name>
      <address>
        <city>York</city>
        <state>Pennsylvania</state>
        <zip>17403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debi Oxenberg</last_name>
      <phone>717-741-8124</phone>
      <email>doxenberg@wellspan.org</email>
    </contact>
    <investigator>
      <last_name>Amit Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UT Southwestern/Simmons Cancer Center - Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liliana Robels</last_name>
      <phone>214-648-8038</phone>
      <email>liliana.robles@utsouthwestern.edu</email>
    </contact>
    <investigator>
      <last_name>Neil Desai, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center/Norris Cancer Ctr. - St. Johnsbury</name>
      <address>
        <city>Saint Johnsbury</city>
        <state>Vermont</state>
        <zip>05819</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>sharon Schoville</last_name>
      <phone>603-650-6056</phone>
      <email>sharon.r.schoville@hitchcock.org</email>
    </contact>
    <investigator>
      <last_name>Alan Hartford, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Quebec - L'Hotel-Dieu de Quebec</name>
      <address>
        <city>Québec City</city>
        <state>Quebec</state>
        <zip>G1R 2J6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josee Allard</last_name>
      <phone>418-525-4444</phone>
      <phone_ext>16730</phone_ext>
      <email>josee.allard@chudequebec.ca</email>
    </contact>
    <investigator>
      <last_name>Eric Vigneault, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CIUSS de l'Estrie - Centre Hospitalier Universitaire de Sherbrooke-Fleurimont</name>
      <address>
        <city>Sherbrooke</city>
        <zip>J1H 5N4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sophie Couture</last_name>
      <phone>819-346-1110</phone>
      <phone_ext>14311</phone_ext>
      <email>sophie.couture.ciussse-chus@ssss.gouv.qc.ca</email>
    </contact>
    <investigator>
      <last_name>Myriam Bouchard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 16, 2019</study_first_submitted>
  <study_first_submitted_qc>January 16, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 18, 2019</study_first_posted>
  <last_update_submitted>July 22, 2020</last_update_submitted>
  <last_update_submitted_qc>July 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Post-prostatectomy</keyword>
  <keyword>Enzalutamide</keyword>
  <keyword>STEEL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Goserelin</mesh_term>
    <mesh_term>Bicalutamide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

